Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Won’t Hold Advisory Meeting to Discuss NDA for Brensocatib
Details : INS1007 (brensocatib), a DPP1 inhibitor, could be the first approved treatment for non-cystic fibrosis bronchiectasis. The company has announced +ve top-line results from its Phase 3 ASPEN study.
Product Name : INS1007
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 24, 2025
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ASPEN Study Subgroup Shows Consistency in Brensocatib’s Efficacy in Bronchiectasis
Details : INS1007 (brensocatib), a DPP1 inhibitor, could be the first approved treatment for non-cystic fibrosis bronchiectasis. The company has announced +ve top-line results from its Phase 3 ASPEN study.
Product Name : INS1007
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 10, 2024
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Goldman Sachs & Co
Deal Size : $650.0 million
Deal Type : Public Offering
Insmed Announces Pricing of $650 Million Public Offering of Common Stock
Details : Insmed intends to use the proceeds to fund continued research and development of INS1007 (brensocatib) as well as pre-commercial and, if approved, commercialization activities related to brensocatib.
Product Name : INS1007
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 30, 2024
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Goldman Sachs & Co
Deal Size : $650.0 million
Deal Type : Public Offering
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Goldman Sachs & Co
Deal Size : $500.0 million
Deal Type : Public Offering
Insmed Announces Proposed $500 Million Public Offering of Common Stock
Details : The net proceeds will fund continued research and development of INS1007 (brensocatib), a small molecule, oral, reversible inhibitor of DPP1, for non-cystic fibrosis bronchiectasis.
Product Name : INS1007
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 28, 2024
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Goldman Sachs & Co
Deal Size : $500.0 million
Deal Type : Public Offering
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Insmed Announces Positive Results from ASPEN Study of Brensocatib in Bronchiectasis
Details : INS1007 (brensocatib), a DPP1 inhibitor, could be the first approved treatment for non-cystic fibrosis bronchiectasis. The company has announced +ve top-line results from its Phase 3 ASPEN study.
Product Name : INS1007
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 28, 2024
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : INS1007 (brensocatib) is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases.
Product Name : INS1007
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 31, 2023
Lead Product(s) : Brensocatib
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amikacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ARIKAYCE is a novel, inhaled, once-daily formulation of amikacin, an established antibiotic that was historically administered intravenously and associated with severe toxicity to hearing, balance, and kidney function.
Product Name : Arikayce
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 28, 2022
Lead Product(s) : Amikacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amikacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Taiba Healthcare
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, taiba will be responsible for the named patient supply program with intent to commercialize ARIKAYCE in the region following receipt of marketing authorization(s) in the territory.
Product Name : Arikayce
Product Type : Antibiotic
Upfront Cash : Undisclosed
June 14, 2021
Lead Product(s) : Amikacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Taiba Healthcare
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Amikacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : First patient was dosed in late December, 2020, in the frontline clinical trial program of ARIKAYCE® (amikacin liposome inhalation suspension) in patients with nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC).
Product Name : Arikayce
Product Type : Antibiotic
Upfront Cash : Inapplicable
April 01, 2021
Lead Product(s) : Amikacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Amikacin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The approval by the MHLW is based on results from the Phase 3 CONVERT study, which demonstrated that once-daily ARIKAYCE, with MDR, improved sputum culture conversion rates in patients with refractory NTM lung disease caused by MAC compared to MDR therap...
Product Name : Arikayce
Product Type : Antibiotic
Upfront Cash : Inapplicable
March 23, 2021
Lead Product(s) : Amikacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable